CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling
CBD Life Sciences (CBDL) is positioning itself for growth amid potential cannabis regulation changes, following former President Trump's support for cannabis legalization and rescheduling to Schedule III. The company, currently in a Letter of Intent with a cannabis dispensary, aims to capitalize on the expanding cannabis market, projected to reach $100 billion by 2030. CEO Lisa Nelson emphasizes CBDL's strategic growth plan to capture market opportunities through product innovation and expanded distribution channels. The global cannabis market, valued at $43.72 billion in 2022, is expected to grow to $444.34 billion by 2030, with North America dominating 81.79% of the market share.
CBD Life Sciences (CBDL) si sta posizionando per una crescita in vista di potenziali cambiamenti nella regolamentazione della cannabis, a seguito del sostegno dell'ex presidente Trump alla legalizzazione della cannabis e alla riclassificazione in Programma III. L'azienda, attualmente in una Letter of Intent con un dispensario di cannabis, mira a capitalizzare sul mercato della cannabis in espansione, previsto per raggiungere 100 miliardi di dollari entro il 2030. L'amministratore delegato Lisa Nelson enfatizza il piano strategico di crescita di CBDL per cogliere opportunità di mercato attraverso l'innovazione dei prodotti e l'espansione dei canali di distribuzione. Il mercato globale della cannabis, valutato 43,72 miliardi di dollari nel 2022, si prevede crescerà fino a 444,34 miliardi di dollari entro il 2030, con il Nord America che domina l'81,79% della quota di mercato.
CBD Life Sciences (CBDL) se está posicionando para el crecimiento en medio de posibles cambios en la regulación de la cannabis, tras el apoyo del ex presidente Trump a la legalización de la cannabis y su reprogramación en la Lista III. La compañía, actualmente en una Carta de Intención con un dispensario de cannabis, tiene como objetivo capitalizar el creciente mercado de la cannabis, que se proyecta alcanzará 100 mil millones de dólares para 2030. La CEO Lisa Nelson enfatiza el plan estratégico de crecimiento de CBDL para capturar oportunidades de mercado a través de la innovación en productos y la expansión de los canales de distribución. Se espera que el mercado global de cannabis, valorado en 43,72 mil millones de dólares en 2022, crezca a 444,34 mil millones de dólares para 2030, con América del Norte dominando el 81,79% de la cuota de mercado.
CBD 라이프 사이언스 (CBDL)는 전 대통령 트럼프의 대마초 합법화 및 Schedule III 재편성 지원에 따라 잠재적인 대마초 규제 변화 도중 성장할 준비를 하고 있습니다. 현재 대마초 판매점과의 의향서(Letter of Intent)를 체결한 이 회사는 2030년까지 1천억 달러에 이를 것으로 예상되는 대마초 시장에서 기회를 포착하는 것을 목표로 하고 있습니다. CEO 리사 넬슨은 CBDL의 전략적 성장 계획을 통해 제품 혁신 및 유통 채널 확대를 통해 시장 기회를 잡는다고 강조합니다. 2022년 글로벌 대마초 시장은 437억 2천만 달러로 평가되었으며, 2030년까지 4444억 3천만 달러로 성장할 것으로 예상됩니다, 북미가 시장 점유율의 81.79%를 차지하고 있습니다.
CBD Life Sciences (CBDL) se positionne pour la croissance à la lumière de changements potentiels dans la réglementation du cannabis, suite au soutien de l'ancien président Trump à la légalisation du cannabis et à son reclassement en Schedule III. L'entreprise, actuellement en lettre d'intention avec un dispensaire de cannabis, vise à capitaliser sur le marché du cannabis en expansion, qui devrait atteindre 100 milliards de dollars d'ici 2030. La PDG Lisa Nelson souligne le plan stratégique de croissance de CBDL pour saisir les opportunités du marché par l'innovation produit et l'élargissement des canaux de distribution. Le marché mondial du cannabis, évalué à 43,72 milliards de dollars en 2022, devrait croître jusqu'à 444,34 milliards de dollars d'ici 2030, avec l'Amérique du Nord dominant 81,79 % de la part de marché.
CBD Life Sciences (CBDL) positioniert sich für Wachstum vor dem Hintergrund möglicher Änderungen in der Cannabisregulierung, nachdem der ehemalige Präsident Trump die Legalisierung von Cannabis und eine Neuregelung in der Liste III unterstützt hat. Das Unternehmen, das sich derzeit in einer Absichtserklärung mit einem Cannabis-Dispensary befindet, verfolgt das Ziel, vom wachsenden Cannabis-Markt zu profitieren, der voraussichtlich bis 2030 100 Milliarden Dollar erreichen wird. CEO Lisa Nelson betont den strategischen Wachstumsplan von CBDL, um Marktchancen durch Produktinnovation und erweiterte Vertriebskanäle zu nutzen. Der globale Cannabis-Markt, der 2022 auf 43,72 Milliarden Dollar geschätzt wurde, wird voraussichtlich auf 444,34 Milliarden Dollar bis 2030 wachsen, wobei Nordamerika 81,79 % des Marktanteils dominiert.
- Company has an active LOI with a cannabis dispensary
- Potential regulatory changes could improve banking access and reduce operational costs
- Operating in a market projected to reach $100 billion by 2030
- North American market dominance with 81.79% share
- None.
The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD 57.18 billion in 2023 to USD 444.34 billion by 2030, exhibiting a CAGR of
SCOTTSDALE, AZ / ACCESSWIRE / November 7, 2024 / With Former President Donald Trump's recent support for cannabis legalization in key U.S. states and calls to reclassify cannabis as a Schedule III drug, CBD Life Sciences, Inc. (OTC PINK:CBDL) is primed to accelerate its growth in the rapidly expanding cannabis and CBD market. This evolving regulatory environment is expected to unlock powerful revenue streams for CBDL, giving the company a strong competitive edge in an industry poised to reach unprecedented heights.
Major Market Opportunity: Riding the
The U.S. cannabis market is projected to exceed
CEO Lisa Nelson: "CBDL Ready to Capture Expansive Market Growth"
"For CBDL, this is a historic moment particularly as the company is currently in a Letter of Intent (LOI) with a cannabis dispensary, positioning itself to capitalize on the growing wave of cannabis legalization." says CEO Lisa Nelson. "With Trump having such significant support from both the public and key political leaders, the market potential is staggering. CBDL's strategic growth plan is designed to capture both the economic impact of increased accessibility and the opportunity to reach millions of new customers nationwide." This moment is especially historic as CBDL is currently in the middle of a Letter of Intent (LOI) with a cannabis dispensary, which aligns perfectly with this new wave of support for cannabis legalization."
CBDL's approach includes product innovation focused on high-quality CBD and cannabis-infused offerings tailored to meet the diverse needs of consumers. As more states pass cannabis-friendly laws, CBDL's distribution channels will expand, enabling the company to maximize its reach in high-demand markets and set new revenue records.
Unlocking Financial Pathways and Reducing Market Barriers
Rescheduling cannabis would not only open more avenues for scientific research but also allow CBD companies like CBDL to benefit from traditional financial and banking services. This anticipated regulatory easing means lower costs, streamlined operations, and increased scalability for CBDL-each of which has a direct impact on shareholder value and revenue growth. With a supportive regulatory environment, CBDL is expected to experience accelerated revenue increases, while establishing a reputation as a leader in research-backed, health-focused cannabis products.
Growing Market Support and Consumer Demand
CBDL's market expansion is also driven by strong consumer support: a recent Pew Research survey revealed that
Link to Article: https://www.usatoday.com/story/news/politics/2024/11/05/donald-trump-marijuana-weed-cannabis-legalization-medical-recreational-election/75970501007/
About CBD Life Sciences, Inc. (CBDL)
CBD Life Sciences, Inc. (CBDL) is committed to delivering premium CBD and cannabis-derived products to meet the needs of a health-conscious and informed consumer base. Focused on innovation, quality, and expansion, CBDL is setting a high standard for growth and leadership in the rapidly expanding cannabis industry.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
|
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is CBD Life Sciences (CBDL) current business expansion plan?
How could Trump's support for cannabis legalization affect CBDL stock?
What is the projected market size for cannabis by 2030?
